Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

In vitro bleeding time with ADP, preliminary

Immunology & Autoimmune

In vitro bleeding time ADPPFA-100/200 ADP closure timePFA-ADP

Review status

Currently under review

Pending specialist review and validation.

What it shows

This test is a screening measure of how well your platelets help form an initial plug to stop bleeding. It uses a device that simulates blood flow through a small opening and exposes your blood to ADP, a natural signal that activates platelets. The result reflects the time it takes for the opening to close under these conditions.

Because it is labeled preliminary, this result is typically part of a broader platelet function assessment. It is often interpreted alongside other tests, such as a second cartridge with a different activator, a complete blood count, and tests for von Willebrand factor.

Why it matters

Your care team may order this test if you have easy bruising, nose or gum bleeding, heavy periods, or if there is a concern about how your platelets function. It can also be considered before procedures when your history suggests a bleeding tendency, or when you are taking medicines that affect platelets.

An abnormal result can point toward platelet function problems or conditions that involve the interaction between platelets and von Willebrand factor. It can also reflect the effect of antiplatelet medications. The result helps guide whether additional testing, medication adjustments, or specialist referral is needed.

Understanding your results

If your result suggests slower closure, your clinician will consider common and reversible reasons first, such as medications, low platelet count, or anemia. They may repeat the test, review how the blood sample was collected, and add targeted tests for von Willebrand factor or platelet function if needed. If your result appears appropriate for your situation, no immediate action may be required beyond routine follow up.

No single test provides a complete picture of bleeding risk. Your symptoms, medical history, medication list, and other lab results are essential for interpretation. Do not stop or change any prescribed medicine on your own; discuss results with your clinician, who will advise on next steps and whether further evaluation is warranted.

Reference ranges

60115 s
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact In vitro bleeding time with ADP, preliminary

  • Antiplatelet medications

    Aspirin, NSAIDs, and P2Y12 inhibitors can prolong results by reducing platelet activation. Always tell your clinician about all prescription and over-the-counter drugs and supplements.

  • Platelet count and hematocrit

    Low platelets or significant anemia can affect closure time independent of true platelet function. Your clinician will review your complete blood count when interpreting the result.

  • Sample collection and handling

    Underfilled citrate tubes, delays to testing, or temperature extremes during transport can alter performance. Proper collection and timely analysis help ensure reliable results.

  • von Willebrand factor levels

    Low von Willebrand factor can slow platelet plug formation with ADP in some settings. Illness, stress, and genetics can influence these levels and the test outcome.

  • Acute inflammation or stress

    Intercurrent illness and inflammation can transiently change platelet reactivity, which may shorten or normalize results. Repeat testing may be considered once you are well.

  • Pregnancy and hormones

    Physiologic changes in pregnancy and with some hormonal therapies can modify platelet and von Willebrand factor activity, affecting test performance.

2026

References

  1. McGill University Health Centre. (2017, March 30). Invitro BT avec ADP Preliminary (Task CD 18477603). Laboratory reference ranges.
  2. James, P. D., Connell, N. T., Ameer, B., Di Paola, J., Eikenboom, J., Giraud, N., Haberichter, S., et al. (2021). ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances.
  3. Favaloro, E. J. (2015). The Platelet Function Analyzer (PFA)-100/200: Analytical considerations and clinical utility. Platelets.